NDAORALGRANULEPriority Review
Approved
Apr 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
COLESTID (colestipol hydrochloride) by Pfizer is clinical pharmacology cholesterol is the major, and probably the sole precursor of bile acids. Approved for hypertension. First approved in 1977.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COLESTID (colestipol hydrochloride) is an oral anion exchange resin that binds bile acids in the intestine, preventing their reabsorption and increasing cholesterol oxidation to bile acids. It is indicated for hypercholesterolemia and works by increasing LDL receptor expression and clearance of cholesterol-rich lipoproteins from plasma. The drug is administered as a granule formulation taken orally.
$0.199MPart D
LOE ApproachingDeclining
COLESTID faces significant market erosion with only $199K in Part D spending and 835 claims in 2023; teams are likely rightsizing with focus on legacy account management rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating…
Worked on COLESTID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.